yeztugo

Generic: lenacapavir sodium

Labeler: gilead sciences, inc.
NDC Directory HUMAN PRESCRIPTION DRUG NDA Inactive Finished

Drug Facts

Product Profile

Brand Name yeztugo
Generic Name lenacapavir sodium
Labeler gilead sciences, inc.
Dosage Form TABLET, FILM COATED
Routes
ORAL
Active Ingredients

lenacapavir sodium 300 mg/1

Manufacturer
Gilead Sciences, Inc.

Identifiers & Regulatory

Product NDC 61958-3401
Product ID 61958-3401_4fcd5eac-41a1-43cd-98c5-f733d5094ff9
Product Type HUMAN PRESCRIPTION DRUG
Marketing Category NDA
Application Number NDA220020
Listing Expiration 2027-12-31
Marketing Start 2025-06-18

Pharmacologic Class

Classes
breast cancer resistance protein inhibitors [moa] cytochrome p450 3a inhibitors [moa] hiv capsid inhibitors [moa] human immunodeficiency virus 1 capsid inhibitor [epc] p-glycoprotein inhibitors [moa]

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 619583401
Hyphenated Format 61958-3401

Supplemental Identifiers

RxCUI
2625890 2625904 2625911 2717197 2717201 2717203
UNII
BDT58WJ9WE

Packaging Origin

Original Packager
true

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name yeztugo (source: ndc)
Generic Name lenacapavir sodium (source: ndc)
Application Number NDA220020 (source: ndc)
Routes
ORAL
source: ndc

Resolved Composition

Strengths
  • 300 mg/1
source: ndc
Packaging
  • 4 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-3401-1)
source: ndc

Packages (1)

61958-3401-1 4 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-3401-1)

Ingredients (1)

lenacapavir sodium (300 mg/1)

Linked Drug Pages (1)

Yeztugo ndc-match (0.9)

Raw FDA Data

View complete raw FDA NDC JSON payload 
{"route": ["ORAL"], "spl_id": "4fcd5eac-41a1-43cd-98c5-f733d5094ff9", "openfda": {"unii": ["BDT58WJ9WE"], "rxcui": ["2625890", "2625904", "2625911", "2717197", "2717201", "2717203"], "spl_set_id": ["1c241af1-ce62-4b0a-9eb7-f6b626174f01"], "manufacturer_name": ["Gilead Sciences, Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "4 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-3401-1)", "package_ndc": "61958-3401-1", "marketing_start_date": "20250618"}], "brand_name": "Yeztugo", "product_id": "61958-3401_4fcd5eac-41a1-43cd-98c5-f733d5094ff9", "dosage_form": "TABLET, FILM COATED", "pharm_class": ["Breast Cancer Resistance Protein Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "HIV Capsid Inhibitors [MoA]", "Human Immunodeficiency Virus 1 Capsid Inhibitor [EPC]", "P-Glycoprotein Inhibitors [MoA]"], "product_ndc": "61958-3401", "generic_name": "LENACAPAVIR SODIUM", "labeler_name": "Gilead Sciences, Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Yeztugo", "active_ingredients": [{"name": "LENACAPAVIR SODIUM", "strength": "300 mg/1"}], "application_number": "NDA220020", "marketing_category": "NDA", "marketing_start_date": "20250618", "listing_expiration_date": "20271231"}